frontiers | Frontiers in Pharmacology

TYPE Correction
PUBLISHED 31 August 2023
DOI 10.3389/fphar.2023.1274075

OPEN ACCESS

EDITED AND REVIEWED BY
Luis Abel Quiñones,
University of Chile, Chile

*CORRESPONDENCE
Laurence McEvoy,
l.mcevoy@liverpool.ac.uk
Munir Pirmohamed,
munirp@liverpool.ac.uk

RECEIVED 07 August 2023
ACCEPTED 15 August 2023
PUBLISHED 31 August 2023

CITATION
McEvoy L, Cliff J, Carr DF, Jorgensen A, Lord R and Pirmohamed M (2023), Corrigendum: *CYP3A* genetic variation and taxane-induced peripheral neuropathy: a systematic review, meta-analysis, and candidate gene study. *Front. Pharmacol.* 14:1274075. doi: 10.3389/fphar.2023.1274075

Corrigendum: *CYP3A* genetic variation and taxane-induced peripheral neuropathy: a systematic review, meta-analysis, and candidate gene study

Laurence McEvoy[1]*, Joanne Cliff[2], Daniel F Carr[1], Andrea Jorgensen[3], Rosemary Lord[2] and Munir Pirmohamed[1]*

[1]Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom, [2]Clatterbridge Cancer Centre, Liverpool, United Kingdom, [3]Health Data Science, University of Liverpool, Liverpool, United Kingdom

KEYWORDS

chemotherapy, cytochrome P450, peripheral neuropathy, personalised medicine, pharmacogenetics

A Corrigendum on
CYP3A genetic variation and taxane-induced peripheral neuropathy: a systematic review, meta-analysis, and candidate gene study

by McEvoy L, Cliff J, Carr DF, Jorgensen A, Lord R and Pirmohamed M (2023). Front. Pharmacol. 14:1178421. doi: 10.3389/fphar.2023.1178421

In the published article, there was an error in the legend and artwork for Figure 2 as published. Additional information relating to variant carriage or non-carriage needed. Forest Plot data was incorrectly reported. The corrected Figure 2 and its caption appears below.

In the published article, there was an error. Meta-analysis data from Figure 2 was incorrectly reported in the **Results**.

A correction has been made to **3 Results**, *3.4 Meta-analysis*, paragraphs 2 and 3. These sentences previously stated:

"For *CYP3A4*22*, sufficient data was available from 2 studies (de Graan et al., 2013; Di Francia et al., 2017). Combining this with the data we generated showed that there was no association between *CYP3A4*22* and PN (OR 1.1; 95% CI 0.62-1.97; I^2 42%; p = 0.74).

For *CYP3A5*3*, sufficient data was available from 2 studies (Eckhoff et al., 2015a; Hu et al., 2016). Combining these two studies with the data from our candidate gene analysis again showed no association between CYP3A5*3 and PN (OR 0.99; 95% CI 0.57-1.71; I^2 = 0%; p = 0.97)."

The corrected sentences appear below:

"For *CYP3A4*22*, sufficient data was available from 2 studies (**de Graan et al., 2013**; **Di Francia et al., 2017**). Combining this with the data we generated showed that there was no association between *CYP3A4*22* and PN (OR 1.22; 95% CI 0.69–2.16; I^2 55%; p = 0.49).

For *CYP3A5*3*, sufficient data was available from 2 studies (**Eckhoff et al., 2015a**; **Hu et al., 2016**). Combining these two studies with the data from our candidate gene analysis again showed no association between CYP3A5*3 and PN (OR 1.15; 95% CI 0.67–1.98; I^2 = 0%; p = 0.61)."

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.



FIGURE 2
Association between *CYP3A4*22* and *CYP3A5*3* variants and taxane-induced peripheral neuropathy. **(A)**. Association between *CYP3A4*22* and taxane-induced peripheral neuropathy. Analysis of **22* carriage (**1/*22* and **22/*22*) vs. non-carriage (**1/*1*). Note: The phenotype definition for cases in Di Francia *et al.* (2017) differed from our phenotype definition of Grade 2 PN and above. Di Francia et al. (2017) considered Grade 1 and above as cases. **(B)**. Association between *CYP3A5*3* and taxane-induced peripheral neuropathy. Analysis of **3* homozygous carriage (**3/*3*) vs. non-carriage and heterozygous carriage (**1/*1* and **1/*3*).

Publisher's note